What is the ticker symbol for 4D pharma?

4D pharma trades under the ticker LBPS on NASDAQ.

What sector does 4D pharma operate in?

4D pharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LBPS in a portfolio?

PortView shows LBPS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

4D pharma (LBPS) Stock Analysis

NASDAQHealthcareBiotechnology

$1.65+0.00%

1-year price historyRange $1.56 – $9.12

52-week range$1.65

$1.50$10.38

What 4D pharma does

4D pharma plc, headquartered in Leeds, UK, and founded in 2014 (originally Schosween 18 Limited), functions as a biopharmaceutical firm dedicated to pioneering live biotherapeutic products (LBPs). The company's diverse pipeline includes several therapeutic candidates aimed at various significant health issues: MRx0518 is being developed to address cancer and immune-oncology diseases. MRx-4DP0004 targets asthma. MRx0029 and MRx0005 are in development for central nervous system disorders. Blautix is intended for irritable bowel syndrome. Thetanix focuses on pediatric Crohn's disease. Additional candidates encompass MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. To drive its discovery efforts, 4D pharma plc utilizes its proprietary MicroRx platform, designed to unearth new LBP candidates for severe illnesses. The company has also established key collaborations: A partnership with Merck KGaA (Darmstadt, Germany) and Pfizer for the assessment of MRx0518. A strategic alliance with the University of Texas MD Anderson for the discovery and development of LBPs within oncology. An agreement with Merck & Co., Inc. involves a clinical trial evaluating the combination of Keytruda and MRx0518 in solid tumor patients, alongside joint initiatives to discover and develop LBPs for vaccine purposes.

Key metrics

Market cap

P/E (TTM)

0.00

EPS (TTM)

$0.00

Beta

3.27

Dividend yield

0.00%

Revenue / share

$0.05

50-day avg

$2.24

200-day avg

$4.28

52-week high

$10.38

52-week low

$1.50

CEO

Duncan Joseph Peyton

ETFs linked to LBPS

Broad-market and Healthcare sector ETFs an investor holding 4D pharma is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how LBPS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze LBPS in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for 4D pharma?: 4D pharma trades under the ticker LBPS on NASDAQ.
Which exchange is LBPS listed on?: LBPS is listed on NASDAQ.
What sector does 4D pharma operate in?: 4D pharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze LBPS in a portfolio?: PortView shows LBPS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.